The 712 North Model
712 North operates as a fully autonomous virtual entity. We have stripped away physical facilities and human managerial latency to ensure 100% of capital is deployed directly into R&D. Our model functions as a lean command center overseen by our founder, Marcel Alavi. We integrate top-tier CRO infrastructure and a specialized advisory network to drive mitochondrial research at scale. By replacing traditional fixed overhead with a software-defined, partner-driven ecosystem, we achieve a level of agility and decision velocity that is impossible within conventional biotech structures.
Meet Our Founder
Marcel V. Alavi, Ph.D. founded 712 North in 2016 to pioneer therapies for fatal age-related diseases by targeting mitochondrial inner membrane proteases. His scientific trajectory began in 2010 when he earned his Ph.D. summa cum laude from Eberhard-Karls University Tübingen, where he investigated genetic eye diseases driven by mitochondrial defects. Following his doctoral work, Marcel held prestigious postdoctoral appointments at the University of California, San Francisco (UCSF) and Johannes-Gutenberg University Mainz, focusing his research on vascular basement membrane defects and intraflagellar transport proteins. As a leading authority in organelle biology, Marcel’s technical leadership is grounded in a prolific research history, including 27 peer-reviewed articles and four patents that serve as the foundation for 712 North's discovery engine.
712 North at the BIO Investor Forum 2019 in San Francisco, CA
Contact us
Interested in learning more or working together? Fill out some info and we will be in touch shortly. We can’t wait to hear from you!